Teladoc Health, Inc. (NYSE:TDOC) Stock Has Average Price Target of $7.54 According to Analysts

Teladoc Health, Inc. (NYSE:TDOC) has received a consensus recommendation of “Hold” from the sixteen brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $7.54.

A number of brokerages have recently commented on TDOC. Canaccord Genuity Group cut their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Bank of America boosted their price target on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Citigroup cut their price target on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a report on Monday, August 3rd.

Insider Buying and Selling at Teladoc Health

In other news, CEO Charles III sold 17,805 shares of Teladoc Health stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares of the company’s stock, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its position in shares of Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock valued at $44,066,000 after acquiring an additional 107,400 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in Teladoc Health during the second quarter valued at approximately $26,864,000. Pale Fire Capital SE boosted its holdings in Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after purchasing an additional 1,454,288 shares in the last quarter. Quantinno Capital Management LP grew its stake in shares of Teladoc Health by 128.0% in the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after purchasing an additional 1,471,631 shares during the period. Finally, Freestone Grove Partners LP bought a new position in shares of Teladoc Health during the 2nd quarter worth approximately $7,338,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Price Performance

NYSE:TDOC opened at $5.68 on Wednesday. The stock has a market cap of $1.03 billion, a P/E ratio of -5.74 and a beta of 2.14. Teladoc Health has a one year low of $4.40 and a one year high of $9.89. The company has a fifty day moving average price of $6.22 and a 200 day moving average price of $6.87.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. The firm had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business’s revenue was down 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, equities research analysts anticipate that Teladoc Health will post -0.92 EPS for the current year.

Teladoc Health Company Profile

Teladoc Health, Inc (NYSE: TDOC) provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company’s offerings include Teladoc’s telehealth services, BetterHelp’s online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.